GLP Watchdog

← Drug-vs-drug verdicts

Rybelsus vs Mounjaro: Oral or Injected, Both for Diabetes

Rybelsus (semaglutide (oral), Novo Nordisk) vs Mounjaro (tirzepatide, Eli Lilly)

Last verified May 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

The verdict

Two diabetes drugs, neither approved for weight management, compared mostly by people who want the weight effect anyway. SURPASS-2 reported −11.2 kg at 40 weeks for Mounjaro; PIONEER 1 reported −4.4 kg at 26 weeks for Rybelsus. Different trials and different durations. Retail sits near $1,029 and $1,069, with Lilly's card requiring commercial insurance. The dosing burden is the honest differentiator: a daily fast, or a weekly injection.

Side-by-side comparison

FieldRybelsusMounjaro
Route & frequencyOral tablet, once daily (empty stomach + 30-min fast)Subcutaneous injection, once weekly
MechanismGLP-1 receptor agonist (semaglutide + SNAC absorption enhancer)Dual GIP / GLP-1 receptor agonist
Blood-sugar reduction at the top dose-1.0% to -1.4% over 26 weeks at 14 mg (PIONEER 1)-2.30% over 40 weeks at 15 mg (SURPASS-2)
Weight lost at the top dose-4.4 kg over 26 weeks at 14 mg (PIONEER 1)-11.2 kg over 40 weeks at 15 mg (SURPASS-2)
Whether food gets in the wayStrictly: empty stomach, no more than 4 oz of plain water, nothing else for 30 minutesNothing to plan around — inject any time, with or without food
What it is approved to treatType 2 diabetes only, since 2019Type 2 diabetes only, since 2022. The same molecule carries the weight label under a different brand
Whether a trial proved it prevents heart attacks and strokesPIONEER 6 showed it was not worse than placebo; it was never sized to show benefitNone yet — SURPASS-CVOT does not report until 2027
What it costs if you pay cashAbout $1,029/mo retailAbout $1,069/mo list, with a savings card for the commercially insured

What each one costs in the compounded market

Standing monthly cash prices from the 556 sellers on this register. These are compounded preparations, not the approved products compared above.

Rybelsus — semaglutide (oral)

from $79 /mo

283 sellers publish a standing price; the median is $174 a month.

Mounjaro — tirzepatide

from $99 /mo

253 sellers publish a standing price; the median is $240 a month.

⚠ A compounded preparation is not the approved product. No agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed when the shortages closed. The price gap is real, and so is the difference in oversight. Every seller, with its price record.

Frequently asked questions

Are Rybelsus and Mounjaro the same drug?

No. Rybelsus is semaglutide (oral) and Mounjaro is tirzepatide — different molecules, and they work differently: GLP-1 receptor agonist (semaglutide + SNAC absorption enhancer) against Dual GIP / GLP-1 receptor agonist. Results with one do not predict results with the other.

Is Rybelsus or Mounjaro cheaper?

On the manufacturers' own cash pricing: Rybelsus at About $1,029/mo retail, Mounjaro at About $1,069/mo list, with a savings card for the commercially insured. ⚠ That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.

What does a compounded version of each actually cost?

Across the 556 sellers in this register, the cheapest standing monthly cash prices we hold are semaglutide (oral) from $79 a month and tirzepatide from $99 a month. ⛔ A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.

Can I switch from Rybelsus to Mounjaro?

Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.

Which one should I ask for?

That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.

References

  1. 1.Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019. PMID: 31186300.
  2. 2.Husain M, Birkenfeld AL, Donsmark M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6). N Engl J Med. 2019. PMID: 31185157.
  3. 3.Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. PMID: 34170647.
  4. 4.Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021. PMID: 34370970.
  5. 5.Novo Nordisk. RYBELSUS (semaglutide) oral tablet — Prescribing Information. DailyMed (NIH/NLM). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  6. 6.Eli Lilly and Company. MOUNJARO (tirzepatide) injection — Prescribing Information. DailyMed (NIH/NLM). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0

Related comparisons

See the full drug-vs-drug verdict index or provider rankings.